论文部分内容阅读
目的探讨HMGA2与DNMT1在膀胱尿路上皮癌中的表达变化及临床意义。方法利用免疫组化方法,以膀胱尿路上皮患者的癌组织及正常人的膀胱组织为研究对象,比较两组患者膀胱组织HMGA2与DNMT1的蛋白的表达水平变化。结果 HMGA2与DNMT1在膀胱尿路上皮癌组织中的阳性表达率分别为65.00%和60.00%,与相对应的对照的正常膀胱组织相比较,HMGA2与DNMT1的表达增高显著,具有显著的统计学差异(P<0.05)。结论 HMGA2与DNMT1基因在膀胱尿路上皮癌的组织当中的过量表达,通过检测和干扰HMGA2与DNMT1基因可能为膀胱尿路上皮的早期诊断和制定治疗方案提供新依据。
Objective To investigate the expression of HMGA2 and DNMT1 in bladder urothelial carcinoma and its clinical significance. Methods The expression of HMGA2 and DNMT1 protein in bladder tissue of two groups were compared by immunohistochemistry, bladder cancer in bladder urothelial tissue and normal bladder tissue. Results The positive expression rates of HMGA2 and DNMT1 in bladder urothelial carcinoma tissues were 65.00% and 60.00%, respectively. Compared with normal bladder tissues, the expression of HMGA2 and DNMT1 increased significantly, with significant statistical difference (P <0.05). Conclusion The overexpression of HMGA2 and DNMT1 in bladder urothelial carcinoma tissues may provide new evidence for the early diagnosis and treatment of bladder urothelial carcinoma by detecting and interfering with HMGA2 and DNMT1 genes.